Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox


Several attempts were made before 1940 to develop a vaccine against meningococcal disease. These early vaccines consisted of either killed whole organisms or crude extracts of broth cultures. Although several investigators demonstrated that antibodies to the group-specific capsular polysaccharide antigens could passively protect mice against the disease, purified preparations failed to work in human volunteers.

With the introduction of antibiotics, the first successful treatment for meningococcal disease, vaccine development became less essential. However, vaccine research and manufacturing techniques were pushed again, when sulfonamide-resistant strains of serogroup C meningococci occurred in 1963 in military personnel in the United States.

 » Printversion

  » find


Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,